Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Adenocarcinoma × olaparib × Clear all

Phase

Status

Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 12 Endometrial Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Breast Neoplasms 4 Neoplasms 3 Uterine Neoplasms 2 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Prostatic Neoplasms 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Renal Cell 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Ovarian Diseases 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Melanoma 1 Laryngeal Neoplasms 1 Kenny-Caffey syndrome, Type 1 1 Hyperglycemia 1 High Grade Serous Ovarian Cancer 1 Head and Neck Neoplasms 1 Genital Neoplasms, Female 1 Genital Diseases, Female 1 Fallopian Tube Neoplasms 1

Interventions

Pemetrexed 4 Docetaxel 4 Capecitabine 4 pembrolizumab 2 icotinib 2 Radiation 2 Oxaliplatin 2 Gemcitabine 2 Gefitinib 2 Drug Therapy 2 Chemoradiotherapy 2 sintilimab 1 rucaparib 1 regorafenib 1 olaparib 1 lenvatinib 1 iron isomaltoside 1000 1 ipatasertib 1 iopromide 1 gluconic acid 1 elemene 1 capecitabine-irinotecan combination 1 aumolertinib 1 atezolizumab 1 anlotinib 1 aflutinib 1 XELOX 1 Telemedicine 1 Surveys and Questionnaires 1 Sorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01682772 2019-08-15

TOPARP

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡